Literature DB >> 9557633

Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus.

L M Lagging1, K Meyer, R J Owens, R Ray.   

Abstract

The putative envelope glycoproteins of hepatitis C virus (HCV) likely play an important role in the initiation of viral infection. Available information suggests that the genomic regions encoding the putative envelope glycoproteins, when expressed as recombinant proteins in mammalian cells, largely accumulate in the endoplasmic reticulum. In this study, genomic regions which include the putative ectodomain of the E1 (amino acids 174 to 359) and E2 (amino acids 371 to 742) glycoproteins were appended to the transmembrane domain and cytoplasmic tail of vesicular stomatitis virus (VSV) G protein. This provided a membrane anchor signal and the VSV incorporation signal at the carboxy termini of the E1 and E2 glycoproteins. The chimeric gene constructs exhibited expression of the recombinant proteins on the cell surface in a transient expression assay. When infected with a temperature-sensitive VSV mutant (ts045) and grown at the nonpermissive temperature (40.5 degrees C), cells transiently expressing the E1 or E2 chimeric glycoprotein generated VSV/HCV pseudotyped virus. The resulting pseudotyped virus generated from E1 or E2 surprisingly exhibited the ability to infect mammalian cells and sera derived from chimpanzees immunized with the homologous HCV envelope glycoproteins neutralized pseudotyped virus infectivity. Results from this study suggested a potential functional role for both the E1 and E2 glycoproteins in the infectivity of VSV/HCV pseudotyped virus in mammalian cells. These observations further suggest the importance of using both viral glycoproteins in a candidate subunit vaccine and the potential for using a VSV/HCV pseudotyped virus to determine HCV neutralizing antibodies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9557633      PMCID: PMC109573          DOI: 10.1128/JVI.72.5.3539-3546.1998

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  65 in total

1.  In vitro replication of hepatitis C virus in a human lymphoid cell line (H9)

Authors:  E Nissen; M Höhne; E Schreier
Journal:  J Hepatol       Date:  1994-03       Impact factor: 25.083

2.  Humoral immune response to hypervariable region 1 of the putative envelope glycoprotein (gp70) of hepatitis C virus.

Authors:  N Kato; H Sekiya; Y Ootsuyama; T Nakazawa; M Hijikata; S Ohkoshi; K Shimotohno
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

3.  Demonstration of in vitro infection of chimpanzee hepatocytes with hepatitis C virus using strand-specific RT/PCR.

Authors:  R E Lanford; C Sureau; J R Jacob; R White; T R Fuerst
Journal:  Virology       Date:  1994-08-01       Impact factor: 3.616

4.  Peptide immunogen mimicry of putative E1 glycoprotein-specific epitopes in hepatitis C virus.

Authors:  R Ray; A Khanna; L M Lagging; K Meyer; Q L Choo; R Ralston; M Houghton; P R Becherer
Journal:  J Virol       Date:  1994-07       Impact factor: 5.103

5.  Inhibition of pestivirus infection in cell culture by envelope proteins E(rns) and E2 of classical swine fever virus: E(rns) and E2 interact with different receptors.

Authors:  M M Hulst; R J Moormann
Journal:  J Gen Virol       Date:  1997-11       Impact factor: 3.891

6.  Vaccination of chimpanzees against infection by the hepatitis C virus.

Authors:  Q L Choo; G Kuo; R Ralston; A Weiner; D Chien; G Van Nest; J Han; K Berger; K Thudium; C Kuo
Journal:  Proc Natl Acad Sci U S A       Date:  1994-02-15       Impact factor: 11.205

7.  Dynamic behavior of hepatitis C virus quasispecies in patients undergoing orthotopic liver transplantation.

Authors:  M Martell; J I Esteban; J Quer; V Vargas; R Esteban; J Guardia; J Gómez
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Processing in the hepatitis C virus E2-NS2 region: identification of p7 and two distinct E2-specific products with different C termini.

Authors:  C Lin; B D Lindenbach; B M Prágai; D W McCourt; C M Rice
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

9.  Prevention of hepatitis C virus infection in chimpanzees after antibody-mediated in vitro neutralization.

Authors:  P Farci; H J Alter; D C Wong; R H Miller; S Govindarajan; R Engle; M Shapiro; R H Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  1994-08-02       Impact factor: 11.205

10.  Genetic drift in hypervariable region 1 of the viral genome in persistent hepatitis C virus infection.

Authors:  N Kato; Y Ootsuyama; H Sekiya; S Ohkoshi; T Nakazawa; M Hijikata; K Shimotohno
Journal:  J Virol       Date:  1994-08       Impact factor: 5.103

View more
  39 in total

1.  N-terminal domain of Borna disease virus G (p56) protein is sufficient for virus receptor recognition and cell entry.

Authors:  M Perez; M Watanabe; M A Whitt; J C de la Torre
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

Review 2.  Studying hepatitis C virus: making the best of a bad virus.

Authors:  Timothy L Tellinghuisen; Matthew J Evans; Thomas von Hahn; Shihyun You; Charles M Rice
Journal:  J Virol       Date:  2007-05-23       Impact factor: 5.103

Review 3.  New therapeutic opportunities for hepatitis C based on small RNA.

Authors:  Qiu-Wei Pan; Scot D Henry; Bob J Scholte; Hugo W Tilanus; Harry L A Janssen; Luc J W van der Laan
Journal:  World J Gastroenterol       Date:  2007-09-07       Impact factor: 5.742

4.  Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector.

Authors:  Heather J Ezelle; Dubravka Markovic; Glen N Barber
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

5.  Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation.

Authors:  Irene S Ludwig; Annemarie N Lekkerkerker; Erik Depla; Fons Bosman; René J P Musters; Stany Depraetere; Yvette van Kooyk; Teunis B H Geijtenbeek
Journal:  J Virol       Date:  2004-08       Impact factor: 5.103

Review 6.  Neutralizing antibodies in hepatitis C virus infection.

Authors:  Mirjam-B Zeisel; Samira Fafi-Kremer; Isabel Fofana; Heidi Barth; Francoise Stoll-Keller; Michel Doffoel; Thomas-F Baumert
Journal:  World J Gastroenterol       Date:  2007-09-28       Impact factor: 5.742

7.  The hypervariable region 1 of the E2 glycoprotein of hepatitis C virus binds to glycosaminoglycans, but this binding does not lead to infection in a pseudotype system.

Authors:  Arnab Basu; Aster Beyene; Keith Meyer; Ranjit Ray
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

8.  Characterization of antibodies induced by vaccination with hepatitis C virus envelope glycoproteins.

Authors:  Ranjit Ray; Keith Meyer; Arup Banerjee; Arnab Basu; Stephen Coates; Sergio Abrignani; Michael Houghton; Sharon E Frey; Robert B Belshe
Journal:  J Infect Dis       Date:  2010-09-15       Impact factor: 5.226

9.  Hepatitis C virus suppresses C9 complement synthesis and impairs membrane attack complex function.

Authors:  Hangeun Kim; Keith Meyer; Adrian M Di Bisceglie; Ranjit Ray
Journal:  J Virol       Date:  2013-03-13       Impact factor: 5.103

10.  Mutagenesis of the fusion peptide-like domain of hepatitis C virus E1 glycoprotein: involvement in cell fusion and virus entry.

Authors:  Hsiao-Fen Li; Chia-Hsuan Huang; Li-Shuang Ai; Chin-Kai Chuang; Steve S L Chen
Journal:  J Biomed Sci       Date:  2009-09-24       Impact factor: 8.410

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.